Biointelli Launches Predict for Life Science Sales

Biointelli Corporation has launched Biointelli Predict, a commercial intelligence platform designed to spot life science organizations entering buying cycles before they appear in a CRM. The company will formally launch the product at the American Association for Cancer Research Annual Meeting in San Diego on April 17, 2026. Built on 18 years of proprietary normalized scientific data, the initial oncology-focused platform covers 17,000 companies and more than 500,000 academic laboratories worldwide. It is aimed at life science manufacturers, distributors, CROs, and scientific services firms.

Scientific Signals Before CRM Activity

Biointelli Predict is built on the company’s Scientific Signal Intelligence methodology, which measures changes in scientific activity as rates of change, called Deltas. The platform draws on NIH and NSF grant awards, industry funding, publication activity indexed through PubMed, USPTO patent filings, lab hiring, clinical trial expansion, citation network growth, and conference abstracts.

“The scientific record is the most accurate leading indicator of life science demand ever assembled. With Biointelli Predict, commercial teams can see purchasing cycles as they begin. Scientific Signal Intelligence makes that possible. It's all about the Delta.”

Oncology Focus for Launch

The company uses an oncology laboratory as an example: a lab receiving a new NIH grant while increasing publications, hiring, and conference participation may be entering a buying cycle for instruments, reagents, and services. Biointelli Predict is intended to identify that acceleration in real time, giving sales teams time to prioritize outreach and tailor messaging while vendor decisions are still being formed.

Biointelli has filed USPTO Provisional Patent Application No. 63/998,284 for the core methodologies. The application was filed on March 6, 2026.

From Signals to Outreach

Biointelli Predict identifies potential commercial opportunities, while BioConnect PRO converts those signals into qualified pipeline through GenAI-powered outreach. Biointelli has supported organizations including Thermo Fisher Scientific and Danaher for more than 14 years, although the company said those references do not imply endorsement of Biointelli Predict or Scientific Signal Intelligence.

Representatives will offer demonstrations at AACR 2026 in San Diego beginning April 17. The platform is positioned for commercial teams that want to find research organizations showing early signs of new purchasing activity.